GlaxoSmithKline Manufacturing SpA

Primary objective: To evaluate the clinical activity of BRd vs. DRd in TI-NDMM subjects; Key secondary objectives: To further evaluate the clinical effectiveness of BRd vs. DRd in TI-NDMM subjects; Secondary objectives: To evaluate the clinical effectiveness of BRd vs. DRd in TI-NDMM subjects; To evaluate the safety and tolerability of BRd vs. DRd in TI-NDMM subjects; To evaluate the safety and tolerability of study treatment based on self-reported symptomatic adverse reactions in TI-NDMM subjects; To evaluate and compare changes in symptoms and their effects on function and HRQoL in TI-NDMM subjects; To characterize the exposure of belantamab mafodotin when co-administered with lenalidomide/dexamethasone in TI-NDMM subjects; To evaluate the ADA of BRd in TI-NDMM subjects

This study aims to confirm the efficacy, safety, PK characteristics and durability of HBsAg suppression of Bepirovirsen 300 mg once a week for 24 weeks (including loading dose) compared with the placebo group. The data of this study are intended to confirm the efficacy of Bepirovirsen in subjects with chronic HBV infection and establish its safety characteristics, providing sufficient basis for evaluating the benefit/risk relationship and supporting its marketing approval.

The purpose of this study is to further evaluate the efficacy, safety, and treatment patterns of Sefortox in real-world clinical practice after approval.